New agents on the horizon in gastric cancer

Annals of Oncology

Volumn 28, Issue 8, 2017, Pages 1767-1775

  Lordick, Florian ^a   Shitara, K ^b   Janjigian, Y Y ^c  

^a University Cancer Center Leipzig (UCCL)   (Germany)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Claudin 18.2; Gastric cancer; HER2; Immunotherapy; STAT3; Stem cell inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; APATINIB; AVELUMAB; CLAUDIN; CLAUDIN 18 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FOLINIC ACID; GELATINASE B; LAPATINIB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RAMUCIRUMAB; REGORAFENIB; STAT3 PROTEIN; TIPIRACIL PLUS TRIFLURIDINE; TRASTUZUMAB; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DNA REPAIR; DRUG EFFICACY; ENZYME INHIBITION; HER2 POSITIVE GASTRIC CANCER; HER2 POSITIVE METASTATIC GASTRIC CANCER; HUMAN; IMMUNE RESPONSE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY ADJUSTED LIFE YEAR; STOMACH CANCER; STROMA; TUMOR MICROENVIRONMENT; DNA DAMAGE; DRUG EFFECTS; GENETICS; IMMUNOTHERAPY; STOMACH TUMOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DNA DAMAGE; DNA REPAIR; HUMANS; IMMUNOTHERAPY; NEOPLASTIC STEM CELLS; STOMACH NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85029283113     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx051     Document Type: Article

References (77)

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386
2. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a populationbased study. Lancet Oncol 2014; 15: 23-34
3. Lin SJ, Gagnon-Bartsch JA, Tan IB et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 2015; 64: 1721-1731
4. Smyth EC, Verheij M, Allum W et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl 5): v38-v49
5. Mohammad NH, ter Veer E, Ngai L et al. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. Cancer Metastasis Rev 2015; 34: 429-441
6. Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218
7. Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012; 61: 673-684
8. Kwak EL, Ahronian LG, Siravegna G et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in METamplified esophagogastric cancer. Cancer Discov 2015; 5: 1271-1281
9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209
10. Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015; 21: 449-456
11. Riches JC, Schultz N, Ku GY et al. Genomic profiling of esophagogastric (EG) tumors in clinical practice. J Clin Oncol 2015; 33(Suppl 3): abstr 57
12. Secrier M, Li X, de Silva N et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 2016; 48: 1131-1141
13. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
14. Satoh T, Xu RH, Chung HC et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study. J Clin Oncol 2014; 32: 2039-2049
15. Lorenzen S, Riera Knorrenschild J, Haag GM et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer 2015; 51: 569-576
16. Kang YK, Shah MA, Ohtsu A et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol 2016; 34(Suppl 4S): abstr 5
17. Tamura K, Shitara K, Naito Y et al. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: phase 1 dose escalation. Ann Oncol 2016; 27(Suppl 6): LBA17
18. Ogitani Y, Aida T, Hagihara K et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising anti-tumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016; 22(20): 5097-5108
19. Hecht JR, Bang YJ, Qin SK et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC-a randomized phase III trial. J Clin Oncol 2016; 34: 443-451
20. Press MF, Ellis CE, Gagnon RC et al. HER2 status in advanced or metastatic gastric, esophageal, or gastro-esophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of lapatinib. Mol Cancer Ther 2017; 16: 228-238
21. Janjigian YY, Sanchez-Vega F, Tuvy Y. Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors. J Clin Oncol 2016; 34(Suppl): abstr 11608
22. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499
23. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489
24. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927
25. Shah MA, Bang YJ, Lordick F et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, METpositive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol 2016 [Epub ahead of print], doi: 10.1001/ jamaoncol.2016.5580
26. Bang YJ, Van Cutsem E, Mansoor W et al. A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. J Clin Oncol 2015; 33(Suppl): abstr 4014
27. Luber B, Deplazes J, Keller G et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2011; 11: 509
28. Dutton SJ, Ferry DR, Blazeby JMet al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 2014; 15: 894-904
29. Kwak EL, LoRusso P, Hamid O. alClinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. J Clin Oncol 2015; 33(Suppl 3): abstr 1
30. Shitara K, Oh DY, Yokota T et al. A phase I study ofMET TKI SAR125844 in Asian patients (pts) with advanced solid tumors. In Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR;Mol Cancer Ther 2015; 14(12 Suppl 2): abstr A167
31. Pearson A, Smyth E, Babina IS et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov 2016; 6: 838-851
32. Boger C, Behrens HM, Mathiak M et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016; 7: 24269-24283
33. Kawazoe A, Kuwata T, Kuboki Y et al. Clinicopathological features of program death ligand-1 (PD-L1) expression with tumor-infiltrating lymphocytes (TILs), mismatch repair (MMR) and Epstein-Barr virus (EBV) status in a large cohort of gastric cancer. Gastric Cancer 2016; doi:.10.1007/s10120-016-0631-3
34. Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med 2015; 373: 1490-1492
35. Muro K, Chung HC, Shankaran V et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717-726
36. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520
37. Janjigian YY, Bendell JC, Calvo E et al. CheckMate-032: phase I/II, openlabel study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol 2016; 34(Suppl): abstr 4010
38. Kang YK et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after 2nd or later line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): a double-blinded, randomized phase III trial. 2017 Gastrointestinal Cancers Symposium, San Francisco, 19 January 2017, abstr 002
39. Yamada Y, Nishina T, Iwasa S et al. A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer. J Clin Oncol 2015; 33(Suppl): abstr 4047
40. Chung HC, Arkenau HT, Wyrwicz L et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: analysis of safety and clinical activity. J Clin Oncol 2016; 34(Suppl): abstr 4009
41. Diaz LA, Uram JN, Wang H et al. Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. J Clin Oncol 2016; 34(Suppl): abstr 3003
42. Herbst RS, Bendell JC, Isambert N et al. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): phase 1a results. J Clin Oncol 2016; 34(Suppl): abstr 3056
43. Voron T, Colussi O, Marcheteau E et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015; 212: 139-148
44. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976
45. Shen L, Li J, Xu J et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2015; 18: 168-176
46. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
47. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235
48. Al-Batran SE, Van Cutsem E, Oh SC et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 2016; 27: 673-679
49. Javle M, Smyth EC, Chau I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res 2014; 20: 5875-5881
50. Yoon HH, Bendell JC, Braiteh FS et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol 2016; 27(12): 2196-2203
51. Cunningham D, Stenning SP, Smyth EC et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma: final results from the UK Medical Research Council randomised ST03 trial. Lancet Oncol 2017 Feb 2 [Epub ahead of print], doi: 10.1016/S1470-2045(17)30043-8; pii: S1470-2045(17)30043-8
52. Fuchs CS, Tabernero J, Tomášek J et al. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer 2016; 115: 974-982
53. Hacker UT, Escalona-Espinosa L, Consalvo N et al. Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial. Br J Cancer 2016; 114: 855-862
54. Shitara K, Muro K, Shimada Y et al. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 2016; 19: 927-938
55. Li J, Qin S, Xu J et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 2016; 34: 1448-1454
56. Chen HD, Zhou J, Wen F et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol 2017; 143(2): 361-368
57. Aprile G, Macerelli M, Giuliani F. Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor. BioDrugs 2013; 27: 213-224
58. Pavlakis N, Sjoquist KM, Marti AJ et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebocontrolled phase II trial. J Clin Oncol 34: 2728-2735
59. Li Y, Rogoff HA, Keates S et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA 2015; 112: 1839-1844
60. Jonker DJ, Nott L, Yoshino T et al. A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Ann Oncol 2016; 27(Suppl 6): abstr 454-O
61. Becerra C, Stephenson J, Jonker DJ et al. Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol 2015; 33(Suppl): abstr 4069
62. Shitara K, Doi T, Nagano O et al. Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). Gastric Cancer 2016; [Epub ahead of print]
63. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1314
64. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789
65. Kusano M, Toyota M, Suzuki H et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106: 1467-1479
66. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9: 759-769
67. Bang YJ, Im SA, Lee KW et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol 2015; 33: 3858-3865
68. Bang Y, Boku N, Chin K et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: phase III GOLD study. Ann Oncol 2016; 27: 1-36
69. Sahin U, Koslowski M, Dhaene K et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 2008; 14: 7624-7634
70. Lordick F, Schuler M, Al-Batran S et al. Claudin 18.2-a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. ESMO Asia Annual Meeting, 19 December 2016, proffered paper session, abstract 220-O
71. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392
72. Shah MA, Starodub A, Wainberg ZA et al. Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric/GE junction tumors. J Clin Oncol 2016; 34(Suppl): abstr 4033
73. Shitara K, Takashima A, Fujitami K et al. Nab-paclitaxel versus solventbased paclitaxel in patients with previously treated advanced gastric cancer: an open-label, randomised phase III trial (ABSOLUTE Trial). Lancet Gastroenterol 2017; doi: http://dx.doi.org/10.1016/S2468-1253(16)30219-9
74. Kang YK, Ryu MH, Park SH et al. Efficacy and safety endings from DREAM: a phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of rst-line chemotherapy [abstract]. J Clin Oncol 2016; 34(Suppl): abstr 4016
75. Hironaka S, Sugimoto N, Yamaguchi K et al. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open label, phase 2 trial. Lancet Oncol 2016; 17: 99-108
76. Bando H, Doi T, Muro K et al. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer 2016; 62: 46-53
77. Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol 2016; 13: 348-360